中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(4): 856-865

Bidirectional association between metabolic associated fatty liver disease and the risk of atherosclerotic cardiovascular disease

DOI: 10.12449/JCH260414
  • 1.

    Department of Catheter Room，Tangshan Workers’Hospital，Tangshan，Hebei 063000，China

  • 2.

    Department of Cardiology，Tangshan Workers’Hospital，Tangshan，Hebei 063000，China

  • 3.

    Department of Geriatrics，Tangshan Workers’Hospital，Tangshan，Hebei 063000，China

  • 4.

    Department of Cardiology，Kailuan General Hospital，Tangshan，Hebei 063000，China

  • 5.

    School of Clinical Medicine，North China University of Science and Technology，Tangshan，Hebei 063000，China

Research funding:

Key Research Program Project of Medical Science and Technology of Hebei Province (20231775)

More Information
  • Corresponding author: HAN Quanle， hanquanle@126.com （ORCID： 0000-0002-3200-9224）
  • Received Date: 2025-09-22
  • Accepted Date: 2025-12-19
  • Published Date: 2026-04-25
    Abstract
  •   Objective  To investigate the association between metabolic associated fatty liver disease （MAFLD） and the risk of atherosclerotic cardiovascular disease （ASCVD）， and to provide data support for the prevention and treatment of such metabolic-associated diseases in clinical practice.  Methods  An observation cohort was established for the workers of Kailuan who underwent physical examination for the first time from June 2006 to October 2007 and had complete liver assessment data， without the history of malignant tumor， MAFLD or ASCVD. According to the presence or absence of MAFLD， the patients were divided into non-MAFLD group with 67 565 patients and MAFLD group with 29 004 patients， and according to the presence or absence of ASCVD， the patients were divided into non-ASCVD group with 69 141 patients and ASCVD group with 481 patients. The group t-test or the Wilcoxon rank-sum test was used for comparison of continuous data between the two groups. The χ2 test was used for comparison of categorical data between the two groups. The life-table method was used to calculate the cumulative incidence rates of new-onset ASCVD and MAFLD； the Kaplan-Meier method was used to plot the survival curves of the cumulative incidence rates of ASCVD in the MAFLD group and the non-MAFLD group and the cumulative incidence rates of MAFLD in the ASCVD group and the non-ASCVD group， and the log-rank test was used for comparison of cumulative incidence rates between two groups. A multivariate Cox proportional-hazards regression model analysis was used to investigate the impact of MAFLD on the risk of ASCVD and the impact of ASCVD on the risk of MAFLD.  Results  Compared with the non-MAFLD group， the MAFLD group had significantly higher levels of body mass index （BMI）， waist circumference， systolic blood pressure （SBP）， diastolic blood pressure （DBP）， resting heart rate， alanine aminotransferase， uric acid （UA）， fasting blood glucose （FBG）， triglyceride （TG）， total cholesterol， low-density lipoprotein cholesterol， and high sensitivity C-reactive protein （hs-CRP）， as well as significanty lower levels of estimated glomerular filtration rate （eGFR） and high-density lipoprotein cholesterol （all P <0.05）. Compared with the non-ASCVD group， the ASCVD group had significantly higher levels of BMI， waist circumference， SBP， DBP， UA， FBG， TG， and hs-CRP and a significantly lower level of eGFR （all P<0.05）. The incidence rate of new-onset ASCVD continued to increase over time in the MAFLD group and the non-MAFLD group， while the incidence rate of new-onset MAFLD firstly increased and then remained stable over time in the ASCVD group and the non-ASCVD group. There were 4 263 cases （14.70%） of new-osnet ASCVD in the MAFLD group， with an incidence density of 12.90 per 1 000 person-years， while there were 6 529 cases （9.66%） of new-osnet ASCVD in the non-MAFLD group， with an incidence density of 8.24 per 1 000 person-years， and there were significant differences in the incidence density and cumulative incidence rate of ASCVD between the two groups （χ2=519.09 and 531.80， both P<0.05）. There were 148 cases （30.77%） of new-onset MAFLD in the ASCVD group， with an incidence density of 40.10 per 1 000 person-years， while there were 32 194 cases （46.56%） of new-onset MAFLD in the non-ASCVD group， with an incidence density of 57.59 per 1 000 person-years， and there were significant differences in the incidence density and cumulative incidence rate of MAFLD between the two groups （χ2=19.29 and 30.78， both P<0.05）. The corrected multivariate Cox proportional-hazards regression model analysis showed that MAFLD was a risk factor for new-onset ASCVD （hazard ratio ［HR］=1.11， 95% confidence interval ［CI］： 1.06 — 1.16， P<0.001）， while ASCVD was a protective factor against new-onset MAFLD （HR=0.72， 95%CI： 0.61 — 0.85， P<0.001）.  Conclusion  There is a significant association between MAFLD and ASCVD， with an increase in the risk of ASCVD in the MAFLD population and a reduction in the risk of MAFLD in the ASCVD population.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    LIM GEH, TANG A, NG CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD[J]. Clin Gastroenterol Hepatol, 2023, 21( 3): 619- 629. DOI: 10.1016/j.cgh.2021.11.038.
    [2]
    WONG MCS, HUANG JLW, GEORGE J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 1): 57- 73. DOI: 10.1038/s41575-018-0055-0.
    [3]
    HAN QL, MAO RY, YU J, et al. Risk factors analysis for prevalence of acute myocardial infarction in young and middle-aged population[J]. Chin Circ J, 2016, 31( 7): 632- 635. DOI: 10.3969/j.issn.1000-3614.2016.07.003.

    韩全乐, 毛瑞英, 郁静, 等. 中青年人群发生急性心肌梗死的危险因素分析[J]. 中国循环杂志, 2016, 31( 7): 632- 635. DOI: 10.3969/j.issn.1000-3614.2016.07.003.
    [4]
    YUE BC, YU J, HAN QL, et al. Risk and risk factors of acute myocardial infarction within 10 years in a young and middle-aged population of a vegion[J]. Chongqing Med, 2020, 49( 11): 1850- 1854. DOI: 10.3969/j.issn.1671-8348.2020.11.029.

    岳博成, 于洁, 韩全乐, 等. 某地区中青年人群10年内急性心肌梗死的风险及危险因素分析[J]. 重庆医学, 2020, 49( 11): 1850- 1854. DOI: 10.3969/j.issn.1671-8348.2020.11.029.
    [5]
    National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2023: An updated summary[J]. Chin Circ J, 2024, 39( 7): 625- 660. DOI: 10.3969/j.issn.1000-3614.2024.07.001.

    国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39( 7): 625- 660. DOI: 10.3969/j.issn.1000-3614.2024.07.001.
    [6]
    LEE H, LEE YH, KIM SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study[J]. Clin Gastroenterol Hepatol, 2021, 19( 10): 2138- 2147. DOI: 10.1016/j.cgh.2020.12.022.
    [7]
    TSUTSUMI T, ESLAM M, KAWAGUCHI T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach[J]. Hepatol Res, 2021, 51( 11): 1115- 1128. DOI: 10.1111/hepr.13685.
    [8]
    TOH JZK, PAN XH, TAY PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2022, 20( 11): 2462- 2473. DOI: 10.1016/j.cgh.2021.09.021.
    [9]
    ZHOU XD, TIAN N, ZHENG MH. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD(2023)[J]. J Clin Hepatol, 2023, 39( 10): 2336- 2339. DOI: 10.3969/j.issn.1001-5256.2023.10.010.

    周晓东, 田娜, 郑明华.《2023年国际多学科专家共识: 代谢相关脂肪性肝病和心血管疾病风险》摘译[J]. 临床肝胆病杂志, 2023, 39( 10): 2336- 2339. DOI: 10.3969/j.issn.1001-5256.2023.10.010.
    [10]
    LIN S, HUANG JF, WANG MF, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40( 9): 2082- 2089. DOI: 10.1111/liv.14548.
    [11]
    DEWIDAR B, KAHL S, PAFILI K, et al. Metabolic liver disease in diabetes- From mechanisms to clinical trials[J]. Metabolism, 2020, 111: 154299. DOI: 10.1016/j.metabol.2020.154299.
    [12]
    SUN DQ, JIN Y, WANG TY, et al. MAFLD and risk of CKD[J]. Metabolism, 2021, 115: 154433. DOI: 10.1016/j.metabol.2020.154433.
    [13]
    KIM D, KONYN P, SANDHU KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol, 2021, 75( 6): 1284- 1291. DOI: 10.1016/j.jhep.2021.07.035.
    [14]
    MOON JH, KIM W, KOO BK, et al. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease[J]. Gut Liver, 2022, 16( 3): 433- 442. DOI: 10.5009/gnl210167.
    [15]
    HOU QQ, QI Q, HAN QL, et al. Association of the triglyceride-glucose index with early-onset atherosclerotic cardiovascular disease events and all-cause mortality: A prospective cohort study[J]. Cardiovasc Diabetol, 2024, 23( 1): 149. DOI: 10.1186/s12933-024-02249-4.
    [16]
    THYGESEN K, ALPERT JS, JAFFE AS, et al. Third universal definition of myocardial infarction[J]. Eur Heart J, 2012, 33( 20): 2551- 2567. DOI: 10.1093/eurheartj/ehs184.
    [17]
    LUO J, THOMASSEN JQ, NORDESTGAARD BG, et al. Neutrophil counts and cardiovascular disease[J]. Eur Heart J, 2023, 44( 47): 4953- 4964. DOI: 10.1093/eurheartj/ehad649.
    [18]
    Chinese Society of Neurology, Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chin J Neurol, 2018, 51( 9): 666- 682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

    中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51( 9): 666- 682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.
    [19]
    Chinese Nutrition Society Obesity Prevention and Control Section, Chinese Nutrition Society Clinical Nutrition Section, Chinese Preventive Medicine Association Behavioral Health Section, et al. Expert consensus on obesity prevention and treatment in China[J]. China Prev Med, 2022, 23( 5): 321- 339. DOI: 10.16506/j.1009-6639.2022.05.001.

    中国营养学会肥胖防控分会, 中国营养学会临床营养分会, 中华预防医学会行为健康分会, 等. 中国居民肥胖防治专家共识[J]. 中国预防医学杂志, 2022, 23( 5): 321- 339. DOI: 10.16506/j.1009-6639.2022.05.001.
    [20]
    Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellitus, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
    [21]
    Hypertension Branch of the Chinese Society of Geriatrics, Beijing Hypertension Prevention and Control Association, National Clinical Research Center for Geriatric Diseases. Chinese guidelines for hypertension management in the elderly 2023[J]. Chin J Hypertens, 2023, 31( 6): 508- 538. DOI: 10.16439/j.issn.1673-7245.2023.06.003.

    中国老年医学学会高血压分会, 北京高血压防治协会, 国家老年疾病临床医学研究中心. 中国老年高血压管理指南2023[J]. 中华高血压杂志, 2023, 31( 6): 508- 538. DOI: 10.16439/j.issn.1673-7245.2023.06.003.
    [22]
    DENG J, QI Q, WU XY, et al. Cohort study on the association between the atherogenic index of plasma and the risk of incident heart failure in a physical examination population[J]. Chin Gen Pract, 2025, 28( 29): 3645- 3652. DOI: 10.12114/j.issn.1007-9572.2025.0087.

    邓洁, 齐祺, 吴欣雨, 等. 血浆致动脉硬化指数与体检人群新发心力衰竭风险的队列研究[J]. 中国全科医学, 2025, 28( 29): 3645- 3652. DOI: 10.12114/j.issn.1007-9572.2025.0087.
    [23]
    WANG XY, ZHANG RS, MAN S, et al. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis[J]. Liver Int, 2023, 43( 8): 1691- 1698. DOI: 10.1111/liv.15591.
    [24]
    CHEN Y, LU C, JU HN, et al. Elevated AIP is associated with the prevalence of MAFLD in the US adults: Evidence from NHANES 2017-2018[J]. Front Endocrinol(Lausanne), 2024, 15: 1405828. DOI: 10.3389/fendo.2024.1405828.
    [25]
    LIU SH, LIU Q, HAN X, et al. Association of trajectories of atherogenic index of plasma with atherosclerotic cardiovascular disease[J]. Chin Circ J, 2024, 39( 7): 676- 681. DOI: 10.3969/j.issn.1000-3614.2024.07.004.

    刘士贺, 刘倩, 韩旭, 等. 血浆致动脉粥样硬化指数轨迹与动脉粥样硬化性心血管疾病的关联[J]. 中国循环杂志, 2024, 39( 7): 676- 681. DOI: 10.3969/j.issn.1000-3614.2024.07.004.
    [26]
    LYU SJ, WU SL, LI JF, et al. Impact of the atherogenic index of plasma on new-onset ischemic stroke[J]. Chin J Cardiov Med, 2024, 29( 3): 198- 204. DOI: 10.3969/j.issn.1007-5410.2024.03.002.

    吕素洁, 吴寿岭, 李金锋, 等. 血浆致动脉粥样硬化指数对新发缺血性脑卒中的影响[J]. 中国心血管杂志, 2024, 29( 3): 198- 204. DOI: 10.3969/j.issn.1007-5410.2024.03.002.
    [27]
    DUAN SJ, REN ZY, ZHENG T, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease[J]. World J Gastroenterol, 2022, 28( 36): 5364- 5379. DOI: 10.3748/wjg.v28.i36.5364.
    [28]
    FERNÁNDEZ-MACÍAS JC, OCHOA-MARTÍNEZ AC, VARELA-SILVA JA, et al. Atherogenic index of plasma: Novel predictive biomarker for cardiovascular illnesses[J]. Arch Med Res, 2019, 50( 5): 285- 294. DOI: 10.1016/j.arcmed.2019.08.009.
    [29]
    WON KB, HEO R, PARK HB, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors[J]. Atherosclerosis, 2021, 324: 46- 51. DOI: 10.1016/j.atherosclerosis.2021.03.009.
    [30]
    ZHU XW, YU LG, ZHOU H, et al. Atherogenic index of plasma is a novel and better biomarker associated with obesity: A population-based cross-sectional study in China[J]. Lipids Health Dis, 2018, 17( 1): 37. DOI: 10.1186/s12944-018-0686-8.
    [31]
    LI YW, KAO TW, CHANG PK, et al. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: A 9-year longitudinal study[J]. Sci Rep, 2021, 11( 1): 9900. DOI: 10.1038/s41598-021-89307-z.
    [32]
    DONGIOVANNI P, PAOLINI E, CORSINI A, et al. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches[J]. Eur J Clin Invest, 2021, 51( 7): e13519. DOI: 10.1111/eci.13519.
    [33]
    DEPRINCE A, HAAS JT, STAELS B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J]. Mol Metab, 2020, 42: 101092. DOI: 10.1016/j.molmet.2020.101092.
    [34]
    YONEDA M, YAMAMOTO T, HONDA Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan[J]. J Gastroenterol, 2021, 56( 11): 1022- 1032. DOI: 10.1007/s00535-021-01828-6.
    [35]
    ZHANG C, ZHU PH, HE LL. Research progress on the correlation between metabolic associated fatty liver disease and cardiovascular disease risk[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 1): 12- 18. DOI: 10.3969/j.issn.1674-7380.2025.01.003.

    张成, 朱平辉, 何玲玲. 代谢相关脂肪性肝病与心血管疾病风险相关性研究现状[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 1): 12- 18. DOI: 10.3969/j.issn.1674-7380.2025.01.003.
    [36]
    Chinese Society of Cardiology, Chinese Medical Association; Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine; Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, et al. Chinese guideline on the primary prevention of cardiovascular diseases in primary health care[J]. Chin J Cardiol, 2023, 51( 4): 343- 363. DOI: 10.3760/cma.j.cn112148-20230106-00014.

    中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南基层版[J]. 中华心血管病杂志, 2023, 51( 4): 343- 363. DOI: 10.3760/cma.j.cn112148-20230106-00014.
    [37]
    WANG LL, YI JY, GUO XL, et al. Associations between life's essential 8 and non-alcoholic fatty liver disease among US adults[J]. J Transl Med, 2022, 20( 1): 616. DOI: 10.1186/s12967-022-03839-0.
    [38]
    BIKOV A, MESZAROS M, KUNOS L, et al. Atherogenic index of plasma in obstructive sleep apnoea[J]. J Clin Med, 2021, 10( 3): 417. DOI: 10.3390/jcm10030417.
    [39]
    CHEN Y, XU LH, MAO YY, et al. Associations of lifestyle scores with nonalcoholic fatty liver disease[J]. Modern Preventive Medicine, 2024, 51( 4): 742- 747. DOI: 10.20043/j.cnki.MPM.202310283.

    陈颖, 徐柳红, 毛盈颖, 等. 生活方式评分与非酒精性脂肪肝的关联性研究[J]. 现代预防医学, 2024, 51( 4): 742- 747. DOI: 10.20043/j.cnki.MPM.202310283.
    [40]
    WEI YX, ZHOU XD, ZHENG MH. Heart and liver co-management:integrated management of metabolic dysfunction-associated steatotic liver disease with cardiovascular disease[J/CD]. Chin J Liver Dis(Electronic Version), 2025, 17( 3): 1- 9. DOI: 10.3969/j.issn.1674-7380.2025.03.001.

    韦艺轩, 周晓东, 郑明华. 心肝共治: 代谢相关脂肪性肝病合并心血管疾病风险的协同管理[J/CD]. 中国肝脏病杂志(电子版), 2025, 17( 3): 1- 9. DOI: 10.3969/j.issn.1674-7380.2025.03.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (34) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return